Multitarget AD-IN-6
Multitarget AD-IN-6 (Compound 39) is a multi-target inhibitor, with an IC50 of 15.54 μM against PDE4B, 15.15 μM against PDE7A, 8.39 μM against PDE3A, and a Kd of 37.7 μM against CHIT1. Multitarget AD-IN-6 acts as a TRPA1 antagonist, reduces the level of the NLRP3 inflammasome multiprotein complex to inhibit its activation, while inhibiting PDE4B, PDE7A and CHIT1, and decreasing the phosphorylation of NF-κB. Multitarget AD-IN-6 improves the pathology of elastase-induced emphysema in mice. Multitarget AD-IN-6 is applicable for the research of chronic obstructive pulmonary disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C28H33N7O5
- 분자량:547.61
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
PDE4B 15.54 μM (IC50) |
PDE7A 15.15 μM (IC50) |
PDE1B 54.47 μM (IC50) |
PDE2A 79.61 μM (IC50) |
PDE3A 8.39 μM (IC50) |
hPDE4D 130.50 μM (IC50) |
PDE5A 26.86 μM (IC50) |
PDE8A 16.46 μM (IC50) |
human PDE 10A 36.13 μM (IC50) |
TRPA1 |
IL-6 |
In Vitro
Multitarget AD-IN-6 inhibits recombinant human PDE4B with an IC50 of 15.54 μM[1].
Multitarget AD-IN-6 inhibits recombinant human PDE7A with an IC50 of 15.15 μM[1].
Multitarget AD-IN-6 inhibits recombinant human PDE1B with an IC50 of 54.47 μM[1].
Multitarget AD-IN-6 inhibits recombinant human PDE2A with an IC50 of 79.61 μM[1].
Multitarget AD-IN-6 inhibits recombinant human PDE3A with an IC50 of 8.39 μM[1].
Multitarget AD-IN-6 inhibits recombinant human PDE4D with an IC50 of 130.50 μM[1].
Multitarget AD-IN-6 inhibits recombinant human PDE5A with an IC50 of 26.86 μM[1].
Multitarget AD-IN-6 inhibits recombinant human PDE8A with an IC50 of 16.46 μM[1].
Multitarget AD-IN-6 inhibits recombinant human PDE10A with an IC50 value of 36.13 μM[1].
Multitarget AD-IN-6 (100 μM) acts as an antagonist of the TRPA1 channel, inhibiting 51% of its activity at a concentration of 100 μM without agonist effects[1].
Multitarget AD-IN-6 inhibits recombinant human CHIT1 with an inhibition rate of 57% and a Kd value of 37.7 μM[1].
Multitarget AD-IN-6 (10 μM; 1 h) inhibits LPS-induced production of nitric oxide, TNF-α, and IL-6 in RAW 264.7 mouse macrophages, exhibiting anti-inflammatory activity[1].
Multitarget AD-IN-6 (10-50 μM; 48 h) reduces fetal bovine serum (FBS)-induced proliferation of bronchial smooth muscle cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human bronchial smooth muscle cells (BSMC)
-
Concentration:10-50 μM
-
Incubation Time:48 h
-
Result:Reduced FBS-induced BSMC proliferation by 38% relative to untreated cells at 10 μM.
Further reduced BSMC proliferation in a concentration-dependent manner at 50 μM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 8-10 weeks old, mean weight 25.5 g, intranasally instilled with porcine pancreatic elastase 4 times weekly for 21 days to induce emphysema)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; once daily; 14 consecutive days
-
Result:Reduced mean linear intercept (MLI) from 59.50 μm to 50.36 μm, attenuating elastase-induced air space enlargement.
Significantly reduced the total number of inflammatory cells in BALF in both acute and chronic experimental settings; in the acute model, this effect was stronger than that of roflumilast.
Normalized PPE-induced elevated transcript levels of pro-inflammatory genes *Tnfa*, *Cxcl2*, *Il6*, and *Il1b* in lung homogenates to control levels.
Reduced PPE-induced increases in NLRP3, ASC/TMS1, and cleaved caspase-1 protein levels in lung homogenates to match control levels.
Decreased PPE-induced NF-κB p65 phosphorylation in lung homogenates to control levels.
Chemical Information
-
분자량 547.61
-
화학식 C28H33N7O5
-
SMILES
CC(C)(C)OC(C1=CC=C(NC(CCCN2C(C(N(C)C(N3C)=O)=O)=C3N=C2NCC4=NC=CC=C4)=O)C=C1)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Hematoxylin-Eosin (H&E) Staining
Hematoxylin-eosin staining is a routine histological method that stains nuclei mainly blue-purple with hemalum and stains cytoplasm, extracellular matrix, and many stromal components pink with eosin, allowing tissue architecture, cell morphology, necrosis, inflammation, fibrosis, tumor growth pattern, and treatment-associated injury to be evaluated by light microscopy. In cancer cells, primary neurons, mouse tumor models, intestinal organoids, inflammatory macrophage preparations, and drug-screening tissues, H&E is a morphology assay rather than a molecular assay; it should be interpreted with complementary molecular or immunostaining assays when the biological question concerns specific proteins, RNA levels, ferroptosis, mitophagy, or immune phenotypes.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)